繁體中文
简体
HOME
ABOUT CHO
TEAM
Board of Directors
Scientific Advisory Board, SAB
PRODUCTS
R&D
PATENTS
NEWS
CAREERS
CONTACT
中文版
NEWS
Home
> News
Title
Date
1
CHO Pharma signs MoU with MetaTech, the first collaboration between regenerative medicine and anti-glycan Antibody
2020-05-29
2
CHO Pharma receives the 16th National Innovation Award - Pharmaceutical Category
2019-12-06
3
Comprehensive Patent Portfolio
2020-03-31
4
CHO Pharma Inc received a critical US patent on glycochemistry
2018-10-04
5
CHO Pharma Inc is listed as company on the emerging stock market and aims to be the TSMC in the biotechnology industry
2017-09-28
6
CHO Pharma Inc Aims to be TSMC in Biotechnology Industry
2017-09-28
7
News Release September 26, 2017:The Cho Pharma Inc will be listed as company on the emerging stock market on September 27.
2017-09-26
8
News Release :The new glycoengineered homogenous anticancer antibody drug of CHO Pharma was approved in the US for Phase I clinical trial.
2017-08-09
9
CHO Pharma is invited by BioTaiwan to present company prospect at “2017 BioBusiness Asia Conference, BBA.”
2017-07-03
10
CHO Pharma’s new drug enters into clinical trial in the US.
2017-03-08
11
Breakthrough in Homogeneous Antibody Development and a New Generation of Glycoarray Technology
2017-01-05
12
Glycan Technology - A New Chapter for Making Antibodies
2017-01-05
13
Academia Sinica Invest Technology Shares in CHO Pharma Inc.
2017-01-05
14
CHO Pharma to present at Boston Taiwanese Biotechnology Symposium
2014-08-21